Pelvic masses: aspiration biopsy with transrectal US guidance

Biplanar, transrectal ultrasound guidance was used in the transrectal aspiration of two pelvic abscesses, one recurrent tumor, and one sterile, nonmalignant fluid collection. This method provides an alternative path that allows precise localization for aspiration biopsy of pelvic masses.     

Nonpalpable cancer of the prostate: assessment with transrectal US

Palpable cancer of the prostate is widely believed to be clinically significant. The authors compared the clinical significance of palpable prostate cancer with nonpalpable prostate cancer discovered with transrectal ultrasound (US). A strong association between lesion volume measured with preoperative transrectal US and volumetric measurements in 60 radical prostatectomy specimens permitted the use of tumor size measured with transrectal US as a reasonable estimation of gross tumor volume. In a subsequent clinical series, 147 biopsy-proved cancers were grouped according to size measured at US, the findings at digital rectal examination (DRE), and the Gleason score. For the 147 patients with known prostate cancer, a statistically significant difference between Gleason scores of palpable and nonpalpable cancers could not be demonstrated when the size of the tumor and its location within the prostate were held constant. Assuming that the Gleason score is a reliable indication of malignant potential and clinical significance, the authors conclude that nonpalpable prostatic cancer detected with transrectal US alone may be just as clinically significant as prostatic cancer discovered with DRE.     

Detection of prostate cancer with three-dimensional transrectal ultrasound: correlation with biopsy results

Objectives

The aim of this study was to evaluate the role of three-dimensional transrectal ultrasound in the diagnosis of prostate cancer.

Methods

A total of 112 patients with elevated serum prostate-specific antigen (PSA) or a positive digital rectal examination were evaluated using three-dimensional greyscale transrectal ultrasound (3D-GS TRUS) and three-dimensional power Doppler sonography (3D-PDS). Target biopsies were obtained together with 12 core systematic biopsies. Pathological results were correlated with the imaging data.

Results

Cancers were detected in 269 biopsy sites from 41 patients. 229 sites of cancer were depicted by 3D-GS TRUS and 213 sites were depicted by 3D-PDS. 30 sites were missed by both 3D-GS TRUS and 3D-PDS. Abnormal prostate images depicted by 3D-GS TRUS and 3D-PDS were associated with lesions with a Gleason score of 6.9 or higher.

Conclusion

The detection rates of prostate cancer were significantly improved with 3D-GS TRUS and 3D-PDS on serum PSA levels >10 ng ml^–1 or 20 ng ml^–1. 3D-GS TRUS and 3D-PDS may improve the biopsy yield by determining appropriate sites for target and systematic biopsies. The abnormalities detected by 3D ultrasound were associated with moderate- and high-grade prostate cancers. However, based on the number of false-negative TRUS results, the use of systematic prostate biopsies should not be eliminated.Prostate cancer is a common malignancy in older males. Previous autopsy studies have shown that one-third of males over 50 years old have latent cancer, yet only 10% develop clinically significant carcinomas during their lifetime [1]. The exact mechanism mediating the progression of microfocal cancers into symptomatic forms of the disease has not been elucidated. Since prostate cancers demonstrate remarkably heterogeneous behaviours ranging from slow-growing lesions to aggressive tumours that metastasise rapidly [2], the diagnosis and treatment of prostate cancers is very challenging. The current methods of screening for prostate cancer include measuring serum prostate-specific antigen (PSA) levels, digital rectal examination and transrectal ultrasound (TRUS) scanning and biopsy. However, controversy surrounds which screening method is the most clinically significant for detecting lesions.Since approximately 20–50% of prostate cancers are invisible by greyscale (GS) TRUS [3], GS TRUS has limited value for detection of prostate cancer [4,5]. In addition, 35% of lesions missed by GS TRUS are moderate- or high-grade tumours [6]. Colour Doppler ultrasound, as an important adjunct to GS TRUS, could improve detection of prostate cancer, although in one study 16% of cases with clinically significant cancer were still missed by this method [7].Three-dimensional (3D) TRUS is a relatively new imaging modality. Preliminary studies have shown improved cancer detection with 3D TRUS when compared with two-dimensional TRUS [8,9]. However, it is still unknown which malignant lesions may be detected by 3D TRUS. Furthermore, 3D TRUS has not been analysed in correlation with the site-specific biopsy pathological results.The purpose of this study was to assess the role of 3D-GS TRUS and 3D power Doppler sonography (3D-PDS) in the diagnosis of prostate carcinoma. This study correlated 3D-GS TRUS and 3D-PDS data with biopsy pathological results using a site-by-site analysis that included target and systematic biopsies.     

MR兼容性气动驱动设备作为经直肠前列腺活检导航的可行性研究

目的评估使用一种与MR兼容的遥控气动驱动机械装置在实时动态3TMR影像引导下进行经直肠前列腺活检的可行性。材料与方法本前瞻性研究经伦理审查委员会     

经直肠和经会阴活检对前列腺癌诊断价值的Meta分析

 目的 系统性比较了经直肠(transrectal, TR)和经会阴(transperineal, TP)前列腺活检对于前列腺癌的诊断价值。方法 通过检索Pubmed、Embase、Web of science、知网和百度学术等数据库,筛选出直到2018-10的可用研究,并对纳入本研究的5篇文献进行Meta分析,计算95%的置信区间内合并的比值比,用来评估TR和TP在前列腺癌检出率方面的差异。本文共纳入了1561例患者,随机分为TR和TP组。结果 Meta分析显示,接受TP前列腺活检的患者与TR组比较,前列腺癌检出率没有显著改善 (OR=1.09, 95% CI 0.95~1.25)。对于血清前列腺特异性抗原(PSA)水平,两组之间也没有统计学差异 (OR=-0.13, 95% CI -0.71~0.45)。对于前列腺体积,两组之间存在统计学差异(OR=-3.28, 95% CI -6.40~-0.6)。结论 meta分析显示TR和经TP活检对前列腺癌的检出率没有统计学差异。     

Palpable prostatic nodules: comparison of US and digital guidance for fine-needle aspiration biopsy

This study was undertaken to evaluate the use of transrectal sonographically guided fine-needle aspiration biopsy and to compare sonographic with digital guidance for biopsy. In 62 patients in whom prostatic carcinoma was suspected at digital rectal examination, fine-needle aspiration biopsies were performed transperineally under sonographic guidance and transrectally under digital guidance. These patients had 89 nodules, 73 of which were sampled with both techniques. Malignant cells were obtained under digital guidance in 17 of 73 nodules (23%) and under sonographic guidance in 16 (22%). An additional seven nodules, which were not seen sonographically, were sampled under digital guidance and proved to be negative. In nine other nodules that were nonpalpable and evident only with sonography, malignant cells were obtained under sonographic guidance in three. These findings indicate that sonographic guidance for fine-needle aspiration biopsy is as good as digital guidance for palpable lesions.     

Comparison of core needle breast biopsy techniques: freehand versus three-dimensional US guidance

RATIONALE AND OBJECTIVES: No single method is generally accepted for evaluating the accuracy of breast biopsy techniques before their clinical implementation. The purpose of this study was to test a new process for evaluating biopsy techniques by using it in the evaluation of a prototype three-dimensional ultrasound (US)-guided biopsy device. MATERIALS AND METHODS: The biopsy accuracy of a new three-dimensional US-guided breast biopsy device was compared to that of the accepted clinical practice of biopsy by expert radiologists with two-dimensional freehand US guidance. Biopsies were performed in chicken tissue phantoms containing 3.2-mm lesions made of poly(vinyl alcohol) cryogel. The criterion for a successful biopsy was the presence of lesion in the sample. The equivalence limit difference tested was 10% by using a power of 90% and a two-sided test significance level, a, of 10%. RESULTS: The biopsy success rate of the three-dimensional US-guided system (96%) was equivalent to that of expert radiologists using two-dimensional freehand US guidance (94.5%) in tissue phantoms containing poly(vinyl alcohol) cryogel lesions. CONCLUSION: This evaluation procedure is a valuable precursor to clinical trials in the assessment of biopsy techniques. The three-dimensional US-guided breast biopsy system provides a suitable alternative to two-dimensional freehand US guidance for biopsy of breast cancer.     

Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer

In contemporary practice, most prostate cancers are either invisible on ultrasound or indistinguishable from concurrent benign prostatic hyperplasia. Diagnosis therefore rests on prostate biopsy. Biopsies are not simply directed at ultrasonically visible lesions, as these would miss many cancers; rather the whole gland is sampled. The sampling itself is systematic, using patterns based on prostate zonal anatomy and the geographical distribution and frequency of cancer. This review explains the evolution of the prostate biopsy technique, from the classical sextant biopsy method to the more recent extended biopsy protocols (8, 10, 12, >12 and saturation biopsy protocols). Extended protocols are increasingly being used to improve diagnostic accuracy, especially in those patients who require repeat biopsy. This trend has been facilitated by the ongoing improvement in safety and acceptability of the procedure, particularly with the use of antibiotic prophylaxis and local anaesthesia. The technical details of these extended protocols are discussed, as are the current data regarding procedure-related morbidity and how this may be minimized.     

Early prostate cancer: diagnostic costs of screening transrectal US and digital rectal examination

A screening study with transrectal ultrasound (US) and digital rectal examination to diagnose early prostate cancer was performed to calculate diagnostic costs. The total costs of screening 784 men were $130,400 with transrectal US and $41,080 with digital rectal examination. Per diagnosed cancer, the costs were $6,520 for transrectal US and $4,108 for digital rectal examination, a difference of 37%. The costs per early diagnosed cancer (stage A or B) were $7,671 and $5,869 for transrectal US and digital rectal examination, respectively--a difference of 23%. The costs per early cancer that would have been advanced if diagnosed without screening were $22,177 for transrectal US and $28,528 for digital rectal examination--a difference of 22% in favor of transrectal US. Equations for these relative costs were generated for transrectal US and digital rectal examination. Costs are related to changes in prevalences and to changes in the stages of prostate cancer when diagnosed without screening.     

经直肠超声引导下穿刺活检在前列腺癌诊断中的临床应用价值

目的 探讨经直肠超声引导下改良6点(6+X)前列腺穿刺活检术在前列腺癌诊断中的临床应用价值.方法 对2013年7月-2015年7月在锦州医科大学附属第一医院就诊的224例临床疑似前列腺癌患者的临床资料进行回顾性分析.所有患者均进行了经直肠超声引导下改良6点前列腺穿刺活检术及手术治疗,将穿刺诊断结果与术后病理结果进行比较.结果 224例疑似前列腺癌患者中,129例经直肠超声引导下改良6点前列腺穿刺术诊断为前列腺癌,90例诊断为前列腺增生,此219例诊断结果与术后病理相符,另5例穿刺活检诊断为前列腺增生而术后病理证实为前列腺癌.穿刺活检诊断前列腺癌的敏感度、特异度、准确度分别为96.3％、100.0％、97.8％,传统的6针法前列腺穿刺术的诊断准确率为93.3％(209/224),两者比较差异有统计学意义(P＜0.05).结论 经直肠超声引导下穿刺活检对于前列腺癌的诊断是一种安全可靠的辅助诊断方法,且改良6点比传统的6针法前列腺穿刺活检术诊断前列腺癌的准确率更高.     

Lymphangiography and fine-needle aspiration biopsy: ineffective for staging early prostate cancer

Four hundred thirty-six patients with carcinoma of the prostate had lymphangiography (LAG) as part of their initial evaluation before treatment. Fine-needle aspiration biopsy (FNAB) of abnormal opacified lymph nodes was performed routinely. The positivity rate of LAG and FNAB in each clinical stage was compared with the positivity rate predicted for that stage, based on published series of patients with carcinoma of the prostate who underwent pelvic lymph node dissection (LND). Within each clinical stage, the relation of the outcome of LAG/FNAB to histologic tumor grade (Gleason score) and serum acid phosphatase levels was evaluated. LAG/FNAB was of very limited value in patients with less than clinical stage C disease and of no value in patients with a Gleason score of less than 6. Although LAG/FNAB is insensitive even in clinical stage C disease, a positive result will avoid the morbidity and expense of a staging LND and allow confident selection of appropriate treatment. A negative LAG/FNAB, on the other hand, is meaningless, because of the high false-negative rate of LAG. Since no two study populations are exactly alike, any evaluation or comparison of tests used to stage patients with carcinoma of the prostate should state the distribution of its patients by clinical stage.     

Mediastinal tumors: biopsy under US guidance

Percutaneous biopsies of mediastinal tumors were successfully performed under sonographic guidance in 14 of 21 patients. In 10 of 11 malignant lesions, malignancy was determined by means of cytologic and histologic examination of the specimens obtained. A histologic diagnosis was reached in seven patients with malignant mediastinal tumors, including all four cases of Hodgkin lymphoma. Mediastinal biopsy under sonographic guidance is a technically simple, rapid, and accurate procedure, but its application is limited to tumors of the anterior mediastinum.     

Multiloculated prostate abscess: treatment with transrectal ultrasound guided transrectal needle aspiration and lavage with the saline and antibiotic

Prostatic abscess is a rare but nevertheless serious disease. It should be diagnosed at an early stage by the combination of clinical examination and transrectal ultrasound, and drained. We treated a 79-year-old case with multiple prostate abscesses (PAs) by using lavage of the saline and antibiotic (cefoxitin) after transrectal ultrasound-guided transrectal puncture and aspiration. We are presenting the transrectal ultrasound images of pre- and postmedication, where we achieved complete success and no relapse was seen in follow-up of 1 year.     

Diffusion MRI predicts transrectal ultrasound biopsy results in prostate cancer detection

Purpose

To evaluate the ability of diffusion tensor imaging (DTI) to predict the transrectal ultrasound (TRUS) biopsy outcomes in persons who have no history of previous TRUS biopsy and present with elevated prostate‐specific antigen (PSA) levels.

Materials and Methods

Thirty‐seven participants underwent DTI, followed by 12‐core TRUS‐guided needle biopsy within 2 weeks. DTI was performed using endorectal coils on a 1.5 Tesla scanner at 1‐mm³ spatial resolution. By comparing with the TRUS biopsy results, the optimum thresholds of the trace apparent diffusion coefficient (tADC) and of the nodular size were investigated. The diagnostic performance of both criteria, the tADC threshold (Criteria A) and the tADC threshold combined with nodular size threshold (Criteria B), were evaluated.

Results

The optimum tADC threshold was 1.0 μm²/ms. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of prostate cancer (PCA) detection for Criteria A were 98%, 89%, 73%, 99%, and 91%, respectively, and were 97%, 98%, 92%, 99% and 98% for Criteria B.

Conclusion

Owing to high negative predictive value, the tADC threshold could be used to exclude subjects with clinically undetectable PCA. Adding the nodular size threshold, the combined threshold could identify the tADC‐positive segments that are likely to yield positive biopsy results. J. Magn. Reson. Imaging 2011;33:356–363. © 2011 Wiley‐Liss, Inc.     

Value of random US-guided transrectal prostate biopsy

One hundred sixty-four men underwent ultrasound-guided transrectal biopsy of a hypoechoic prostatic nodule suspicious for malignancy, and random biopsy of normal-appearing areas of the gland. The contribution of random biopsy to diagnosis, staging, and management of prostatic carcinoma was evaluated. A diagnosis of carcinoma was made in 71 patients (43.3%). Carcinoma was diagnosed at biopsy of only the nodule in 56 of these patients (79%), at both the nodule and random biopsy site in 10 (14%), and only at the random biopsy site in five (7%). Random biopsy did not result in significant alteration of clinical staging. However, management was altered in five patients with positive results at random biopsy only, four of whom underwent surgery. The additional yield from random prostatic biopsy was small but distinct and had clinical relevance. The authors conclude that random biopsy is a useful procedure in the evaluation of patients with prostatic nodules.